Dr. Almath Spooner:

Also, it would have been an agent that would have gone through the EU referral process by the licensing committee, the Committee for Medicinal Products for Human Use, CHMP, for the harmonisation of product information. We would like to understand why historically there might have been some differences. We need to carry out a piece of work to analyse whether there were substantial differences. I am sure we will be happy to discuss the matter with Mr. Peter Murphy and his colleagues and update the joint committee should it be necessary to do so.